Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dietary Supplements Blossom As Revenue Growth Ingredients For Big Pharma

This article was originally published in The Tan Sheet

Executive Summary

Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients

You may also be interested in...



Supplement-To-Drug Applications Look Like The Next Wave To Some Experts

FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts

Supplement-To-Drug Applications Look Like The Next Wave To Some Experts

FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts

Supplement-To-Drug Applications Look Like The Next Wave To Some Experts

FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts

Related Content

Topics

UsernamePublicRestriction

Register

PS101714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel